Abstract
Objectives Given the current pandemic, there is an urgent need to identify effective, safe treatments for COVID-19 (coronavirus disease). A systematic benefit-risk assessment was designed and conducted to strengthen the ongoing monitoring of the benefit-risk balance for chloroquine and hydroxychloroquine in COVID-19 treatment.
Methods The overall benefit-risk of the use of chloroquine or hydroxychloroquine as a treatment for COVID-19 compared to standard of care, placebo or other treatments was assessed using the Benefit-Risk Action Team (BRAT) framework. We searched PubMed and Google Scholar to identify literature reporting clinical outcomes in patients taking chloroquine or hydroxychloroquine for COVID-19. A value tree was constructed and key benefits and risks were ranked by two clinicians in order of considered importance.
Results Several potential key benefits and risks were identified for use of hydroxychloroquine or chloroquine in COVID-19 treatment. For the benefit of virological clearance, three studies were identified. A significant risk difference (RD) between hydroxychloroquine and the comparator group (standard of care) was found for only one study (RD=0.58, 95% CI: 0.17, 0.98). The risk difference was not significant for the other two studies (RD=-0.07, 95% CI:- 0.75, 0.61 and RD=0.08, 95% CI:-0.74, 0.91). In addition, no significant risk difference between hydroxychloroquine and the comparator group (standard of care) was identified for the risk of abnormal liver function tests (LFTs) (RD=0.07, 95% CI: -0.28, 0.41).
Conclusions Overall, no conclusion can be made on the benefit-risk profile of hydroxychloroquine or chloroquine in the treatment of COVID-19 compared to standard of care, placebo or other treatments at this time. Whilst the availability of comparative data are limited, the current framework summarises the key anticipated benefits and risks. As further data from clinical trials and real world use on these benefits and risks becomes available, this can be incorporated into the framework for an ongoing benefit-risk assessment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Drug Safety Research Unit (DSRU) is an independent academic institution which works in association with the University of Portsmouth. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in this analysis are available from the references supplied.
